期刊
TRENDS IN NEUROSCIENCES
卷 33, 期 11, 页码 513-523出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tins.2010.08.002
关键词
-
资金
- CIHR [MOP-12699]
- Cure Huntington Disease Initiative (CHDI)
- Canadian Institutes of Health Research (CIHR) - Huntington Society of Canada (HSC)
Investigations of synaptic transmission and plasticity in mouse models of Huntington's disease (HD) demonstrate neuronal dysfunction long before the onset of classical disease indicators. Similarly, recent human studies reveal synaptic dysfunction decades before predicted clinical diagnosis in HD gene carriers. These studies guide premanifest tracking of disease and the development of treatment assessment tools. New discoveries of mechanisms underlying early neuronal dysfunction, including elevated pathogenic extrasynaptic NMDA receptor signaling, reduced synaptic connectivity and loss of brain-derived neurotrophic factor (BDNF) support have led to pharmacological interventions that can reverse or delay phenotype onset and disease progression in HD mice. Further understanding the primary effects of gene mutations associated with late-onset neurodegeneration should translate to novel treatments for HD families and guide therapeutic strategies for other neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据